Renee P. Tannenbaum
CIK: 0001543174
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jun 11, 2026CRDF
Cardiff Oncology, Inc.
Award(A)DirectStock Options
40.6K shares- - May 21, 2026ANIP
ANI PHARMACEUTICALS INC
Award(A)Direct4.4K shares- - Dec 5, 2025ANIP
ANI PHARMACEUTICALS INC
Sale(S)Direct1.8K shares at avg. $81.15$146K - Jun 26, 2025CRDF
Cardiff Oncology, Inc.
Award(A)DirectStock Options
40.6K shares- - May 22, 2025ANIP
ANI PHARMACEUTICALS INC
Award(A)Direct4.3K shares- - Dec 12, 2024CRDF
Cardiff Oncology, Inc.
Purchase(P)Direct10K shares at avg. $3.42$34K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 11, 2026 |  CRDF Cardiff Oncology, Inc. | Award(A) Stock Options | 40,565 | - | - | Direct |
| May 21, 2026 |  ANIP ANI PHARMACEUTICALS INC | Award(A) | 4,357 | - | $0 | Direct |
| Dec 5, 2025 | ANIP ANI PHARMACEUTICALS INC | Sale(S) | 1,800 | $81.15 | $146,070 | Direct |
| Jun 26, 2025 | CRDF Cardiff Oncology, Inc. | Award(A) Stock Options | 40,565 | - | - | Direct |
| May 22, 2025 | ANIP ANI PHARMACEUTICALS INC | Award(A) | 4,336 | - | - | Direct |
| Dec 12, 2024 | CRDF Cardiff Oncology, Inc. | Purchase(P) | 10,000 | $3.42 | $34,224 | Direct |
1-6 of 6 transactions
About TANNENBAUM RENEE P
TANNENBAUM RENEE P (SEC CIK 0001543174) files insider reports with the SEC as Director of Cardiff Oncology, Inc. (CRDF) and Director of ANI PHARMACEUTICALS INC (ANIP).
Signal8 holds 6 ownership filings by TANNENBAUM RENEE P, all Form 4s, filed between Dec 16, 2024 and Jun 15, 2026. Those filings report 6 transactions, from Dec 12, 2024 to Jun 11, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on TANNENBAUM RENEE P's filings is in PRINCETON, NJ.
Recent filings by TANNENBAUM RENEE P
- Jun 11, 2026: Grant or award of CRDF derivative securities (Form 4, code A).
- May 21, 2026: Grant or award of ANIP shares (Form 4, code A).
- Dec 5, 2025: Open-market sale of ANIP shares (Form 4, code S).
- Jun 26, 2025: Grant or award of CRDF derivative securities (Form 4, code A).
- May 22, 2025: Grant or award of ANIP shares (Form 4, code A).
Other insiders filing for Cardiff Oncology, Inc. (CRDF)
- Alland Leila, Chief Medical Officer
- PACE GARY W, Director
- Mohindru Mani, Chief Executive Officer
- Armitage James O, Director
- White Lale, Director
- Markin Rodney S, Director